CorNeat Vision, a clinical-stage, biomimetic implants and technology company based in Israel, has received 510(k) FDA clearance for its product, EverPatch, a synthetic tissue substitute for use in ophthalmic surgery. The company believes the sterile, non-degradable substitute will eventually replace the use of donor and processed tissue for ocular surgeries, eliminating the risk of disease transmission.
EverPatch is significantly thinner than processed patch tissue and provides better handling than these alternatives, the company states. The product’s holes allow for more accurate positioning and anchoring, and facilitate direct conjunctival adhesion to the sclera, allowing for more seamless bio-integration.
The patch is designed to be long-lasting and immunologically inactive, and makes use of CorNeat’s tissue-integrating material technology, EverMatrix, which was developed for the company’s corneal prosthesis program and is the only synthetic non-degradable patch material currently available for ocular surgery in the US. CorNeat plans to launch EverPatch in leading ophthalmic centers around the country later this year.
